ASX Linkedin Twitter               

 

Scientific Presentations 2017

 

Presentation Title Conference Date
 CAPRA: A Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients. Society for Immunotherapy of Cancer – 32nd Annual Meeting, Washington DC United States  8-12 November 2017

(Poster Session 12.30-8pm 10, 11 November)

 Pre-clinical activity of a novel immunotherapy combination of CAVATAK (Coxsackievirus A21), anti-PD1 blockade and an IDO inhibitor in melanoma Society for Immunotherapy of Cancer – 32nd Annual Meeting, Washington DC United States  8-12 November 2017

(Poster Session 12.30-8pm 10, 11 November)

Podium Presentation: CAVATAK and Pembrolizumab Results Society for Immunotherapy of Cancer – 32nd Annual Meeting, Washington DC United States  5.10pm EST 10 November 2017

Session: Oncolytics Viruses and Intratumoral Therapies

Phase I/II CANON study: Oncolytic immunotherapy for Non-Muscle Invasive Bladder Cancer (NMIBC) using Intravesical Coxsackievirus A21 2017 EACR-AACR-SIC Special Conference, Florence, Italy 25 June 2017

Translational Research I poster session (abstract 496)

Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago IL USA 05 June 2017

Hall A – Poster Board 109 (8:00-11:30am).

Poster presentation held in Hall D1 (4:45-6:00pm)

Keynote-200 phase 1b: A novel combination study of intravenously delivered Coxsackievirus A21 and pembrolizumab in advanced cancer patients 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago IL USA 05 June 2017

Hall A – Poster Board 194b (8:00-11:30am)

Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial American Association for Cancer Research (AACR) Annual Meeting 2017, Washington DC USA 3 April 2017
The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment American Association for Cancer Research (AACR) Annual Meeting 2017, Washington DC USA 4 April 2017
Phase 1b KEYNOTE-200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients American Association for Cancer Research (AACR) Annual Meeting 2017, Washington DC USA 4 April 2017

 

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).